Yanru Qin

机构：Guangxi University, China Pharmaceutical University, Xuzhou Medical College, Huaian First People’s Hospital, Nanjing Drum Tower Hospital, Second People’s Hospital of Huai’an, First Affiliated Hospital of Zhengzhou University, Hebei University · ORCID：0000-0003-2175-9617

发表论文 241 篇 · 总被引 6536 次 · h-index 38

代表论文

• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results (2024 · Nature Medicine · 被引 194)
• Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial (2025 · The Lancet · 被引 128)
• CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial (2025 · Nature Medicine · 被引 40)
• Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial (2024 · Nature Medicine · 被引 35)
• Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study. (2024 · Journal of Clinical Oncology · 被引 19)
• GPRC5A promotes lung colonization of esophageal squamous cell carcinoma (2024 · Nature Communications · 被引 12)